Nanobiotix Announces First Data from Phase 1 Study on NBTXR3 as Second Line Therapy for Locally Advanced Non-Small Cell Lung Cancer
Paris, France and Cambridge, Massachusetts – Nanobiotix, a pioneering late-stage clinical biotechnology company, has announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center. This study is evaluating NBTXR3 (JNJ-1900), a radiotherapy-activated nanotherapy, as a second or later line (2L+) therapy for patients with locally advanced non-small cell lung cancer (NSCLC) amenable to re-irradiation.
Background on Nanobiotix and NBTXR3
Nanobiotix is a biotechnology company dedicated to developing disruptive nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients. NBTXR3 is a nanoparticle-based therapeutic that is designed to be activated by radiotherapy, releasing its therapeutic payload directly at the tumor site. This targeted approach allows for increased efficacy while minimizing potential side effects.
Study Findings
The Phase 1 study, which is being led by principal investigator Dr. Saumil Gandhi at MD Anderson, is designed to evaluate the safety, tolerability, and dose-escalation of NBTXR3 in combination with radiotherapy in patients with locally advanced NSCLC. The data presented at the 2025 European Lung Cancer Conference will include the initial findings from the dose escalation part of the study.
Impact on Patients
For patients with locally advanced NSCLC, the current treatment options are limited. Once a patient has undergone initial radiation therapy, there are few effective treatments for tumors that persist or recur. The potential for a second line therapy like NBTXR3 could offer new hope for these patients. The data from the Phase 1 study will provide valuable insights into the safety, efficacy, and optimal dosing of NBTXR3 as a second line therapy.
Impact on the World
If successful, NBTXR3 could represent a major breakthrough in the treatment of locally advanced NSCLC. By offering a targeted, nanotherapeutic approach that can be used in combination with radiotherapy, Nanobiotix has the potential to significantly improve treatment outcomes for patients and reduce the burden of disease. Furthermore, this innovation could pave the way for the development of similar nanotherapeutics for other types of cancer.
Conclusion
The first data from the completed dose escalation part of Nanobiotix’s Phase 1 study evaluating NBTXR3 as a second or later line therapy for patients with locally advanced NSCLC represents an important step forward in the development of this innovative nanotherapeutic approach. The data, which will be presented at the 2025 European Lung Cancer Conference, will provide valuable insights into the safety, tolerability, and efficacy of NBTXR3 as a potential new treatment option for patients with limited options. The potential impact of this innovation on both individual patients and the global cancer community is significant, and the results of this study will be closely watched by the scientific community and those affected by NSCLC.
- Nanobiotix announces first data from Phase 1 study on NBTXR3 as second line therapy for locally advanced NSCLC
- Study sponsored by MD Anderson evaluating safety, tolerability, and optimal dosing of NBTXR3 in combination with radiotherapy
- NBTXR3 represents a major breakthrough in the treatment of locally advanced NSCLC
- Data to be presented at the 2025 European Lung Cancer Conference by study principal investigator, Dr. Saumil Gandhi
